Increased expression levels of WAVE3 are associated with the progression and metastasis of Triple Negative Breast Cancer

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Kulkarni, Swati ^a   Augoff, Katarzyna ^b   Rivera, Louis ^c   McCue, Brian ^b   Khoury, Thaer ^d   Groman, Adrienne ^d   Zhang, Li ^b   Tian, Lili ^d   Sossey Alaoui, Khalid ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN WAVE3; REGULATOR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS POTENTIAL; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

ACTINS; BREAST NEOPLASMS; CYTOSKELETON; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; RECURRENCE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WISKOTT-ALDRICH SYNDROME PROTEIN FAMILY;

EID: 84865418690     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042895     Document Type: Article

References (55)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300 doi: 10.3322/caac.20073.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752 doi: 10.1038/35021093.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874 doi: 10.1073/pnas.191367098.
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423 doi: 10.1073/pnas.0932692100.
5. Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP, (2007) Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 24: 587-597 doi: 10.1007/s10585-007-9114-6.
6. Chiang AC, Massague J, (2008) Molecular basis of metastasis. N Engl J Med 359: 2814-2823 doi: 10.1056/NEJMra0805239.
7. Savagner P, (2001) Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23: 912-923 doi: 10.1002/bies.1132.
8. Spaderna S, Schmalhofer O, Hlubek F, Jung A, Kirchner T, et al. (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh Dtsch Ges Pathol 91: 21-28.
9. Nguyen DX, Massague J, (2007) Genetic determinants of cancer metastasis. Nat Rev Genet 8: 341-352 doi: 10.1038/nrg2101.
10. Nguyen DX, Bos PD, Massague J, (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284 doi: 10.1038/nrc2622.
11. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, et al. (2011) Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 13: 202 doi: 10.1186/bcr2789.
12. Taylor MA, Parvani JG, Schiemann WP, (2010) The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 15: 169-190 doi: 10.1007/s10911-010-9181-1.
13. Yang J, Weinberg RA, (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829 doi: 10.1016/j.devcel.2008.05.009.
14. Anders C, Carey LA, (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22: 1233-1239.
15. Anders CK, Carey LA, (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9Suppl 2: S73-S81 doi: 10.3816/CBC.2009.s.008.
16. Carey L, Winer E, Viale G, Cameron D, Gianni L, (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692 doi: 10.1038/nrclinonc.2010.154.
17. Finnegan TJ, Carey LA, (2007) Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 3: 55-63 doi: 10.2217/14796694.3.1.55.
18. Foulkes WD, Smith IE, Reis-Filho JS, (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948 doi: 10.1056/NEJMra1001389.
19. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, et al. (2011) RB1 and p53 at the crossroad of EMT and triple negative breast cancer. Cell Cycle 10.
20. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, et al. (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14: 8010-8018 doi: 10.1158/1078-0432.CCR-08-1208.
21. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, et al. (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15: 2302-2310 doi: 10.1158/1078-0432.CCR-08-2132.
22. Gupta GP, Massague J, (2006) Cancer metastasis: building a framework. Cell 127: 679-695 doi: 10.1016/j.cell.2006.11.001.
23. Padua D, Massague J, (2009) Roles of TGFbeta in metastasis. Cell Res 19: 89-102 doi: 10.1038/cr.2008.316.
24. Sossey-Alaoui K, Ranalli TA, Li X, Bakin AV, Cowell JK, (2005) WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression. Exp Cell Res 308: 135-145.
25. Sossey-Alaoui K, Li X, Cowell JK, (2007) c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration. J Biol Chem 282: 26257-26265 doi: 10.1074/jbc.M701484200.
26. Sossey-Alaoui K, Downs-Kelly E, Das M, Izem L, Tubbs R, et al. (2011) WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int J Cancer 129: 1331-1343 doi: 10.1002/ijc.25793.
27. Sossey-Alaoui K, Safina A, Li X, Vaughan MM, Hicks DG, et al. (2007) Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells. Am J Pathol 170: 2112-2121 doi: 10.2353/ajpath.2007.060975.
28. Sossey-Alaoui K, Li X, Ranalli TA, Cowell JK, (2005) WAVE3-mediated cell migration and lamellipodia formation are regulated downstream of phosphatidylinositol 3-kinase. J Biol Chem 280: 21748-21755.
29. Bloom HJ, Richardson WW, (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377.
30. Elston CW, Ellis IO, (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
31. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, et al. (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978.
32. Allred DC, Harvey JM, Berardo M, Clark GM, (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168.
33. Sossey-Alaoui K, Bialkowska K, Plow EF, (2009) The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem 284: 33019-33029 doi: 10.1074/jbc.M109.034553.
34. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408 doi: 10.1006/meth.2001.1262.
35. Schmittgen TD, Livak KJ, (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
36. Oda A, Miki H, Wada I, Yamaguchi H, Yamazaki D, et al. (2005) WAVE/Scars in platelets. Blood 105: 3141-3148 doi: 10.1182/blood-2003-04-1319.
37. Sossey-Alaoui K, Su G, Malaj E, Roe B, Cowell JK, (2002) WAVE3, an actin-polymerization gene, is truncated and inactivated as a result of a constitutional t(1;13)(q21;q12) chromosome translocation in a patient with ganglioneuroblastoma. Oncogene 21: 5967-5974.
38. Oda A, Miki H, Wada I, Yamaguchi H, Yamazaki D, et al. (2004) WAVE/Scars in Platelets. Blood 105: 3141-3148.
39. Feng L, Xie Y, Zhang H, Wu Y, (2012) miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol 29: 856-863 doi: 10.1007/s12032-011-9823-1.
40. Bray I, Tivnan A, Bryan K, Foley NH, Watters KM, et al. (2011) MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 303: 56-64 doi: 10.1016/j.canlet.2011.01.016.
41. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, et al. (2010) Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol 176: 2113-2130 doi: 10.2353/ajpath.2010.090837.
42. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, et al. (2009) Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 9: 293-301 doi: 10.1159/000186051.
43. Lin SL, Chang DC, Ying SY, Leu D, Wu DT, (2010) MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res 70: 9473-9482 doi: 10.1158/0008-5472.CAN-10-2746.
44. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261 doi: 10.1073/pnas.0510565103.
45. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791.
46. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, et al. (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23: 1420-1430.
47. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, et al. (2007) Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 7: 471-479.
48. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, et al. (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12: 4218-4224.
49. Lobodasch K, Frohlich F, Rengsberger M, Schubert R, Dengler R, et al. (2007) Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: An increase in cell number at completion of therapy is a predictor of early relapse. Breast 16: 211-218.
50. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, et al. (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13: 920-928.
51. Ring A, Smith IE, Dowsett M, (2004) Circulating tumour cells in breast cancer. Lancet Oncol 5: 79-88.
52. Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, et al. (2007) Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 18: 851-858 doi: 10.1093/annonc/mdl502.
53. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, et al. (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20: 3404-3412.
54. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M, (2005) Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 92: 906-912.
55. Gupta GP, Massague J, (2006) Cancer metastasis: building a framework. Cell 127: 679-695 doi: 10.1016/j.cell.2006.11.001.